Cargando…

Designed construction of tween 60@2β-CD self-assembly vesicles as drug delivery carrier for cancer chemotherapy

We report a simple strategy to prepare Tween 60@2β-CD self-assembly vesicles in aqueous solution as a new drug delivery carrier for cancer chemotherapy. The spherical shape of vesicles was confirmed by transmission electron microscopy (TEM) and mean particle sizes were about 33.7 nm, as measured by...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Yue, Zhang, Qin, Yan, Yun, Gong, Miaomiao, Zhao, Qi, Bao, Zhihong, Liu, Kaerdun, Wang, Siling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7025689/
https://www.ncbi.nlm.nih.gov/pubmed/29463124
http://dx.doi.org/10.1080/10717544.2018.1440448
_version_ 1783498555846033408
author Yuan, Yue
Zhang, Qin
Yan, Yun
Gong, Miaomiao
Zhao, Qi
Bao, Zhihong
Liu, Kaerdun
Wang, Siling
author_facet Yuan, Yue
Zhang, Qin
Yan, Yun
Gong, Miaomiao
Zhao, Qi
Bao, Zhihong
Liu, Kaerdun
Wang, Siling
author_sort Yuan, Yue
collection PubMed
description We report a simple strategy to prepare Tween 60@2β-CD self-assembly vesicles in aqueous solution as a new drug delivery carrier for cancer chemotherapy. The spherical shape of vesicles was confirmed by transmission electron microscopy (TEM) and mean particle sizes were about 33.7 nm, as measured by dynamic light scattering, micro-IR results indicated that the self-assembly vesicles was driven by hydrogen bonding. Hydrophilic doxorubicin (DOX) was successfully loaded into the self-assembly vesicles with drug loading content of 7.85% and loading efficiency of 42%. In addition, an in vitro cytotoxicity study and cellular uptake assays demonstrated that the DOX-loaded Tween 60@2β-CD vesicles markedly enhanced the cellular uptake and cytotoxicity of DOX toward the Hela cells. Furthermore, when used to evaluate the in vivo therapeutic efficacy in mice bearing the breast cell line (4T1), DOX-loaded vesicles exhibited superior inhibition of tumor growth compared with the DOX solutions.
format Online
Article
Text
id pubmed-7025689
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-70256892020-02-27 Designed construction of tween 60@2β-CD self-assembly vesicles as drug delivery carrier for cancer chemotherapy Yuan, Yue Zhang, Qin Yan, Yun Gong, Miaomiao Zhao, Qi Bao, Zhihong Liu, Kaerdun Wang, Siling Drug Deliv Research Article We report a simple strategy to prepare Tween 60@2β-CD self-assembly vesicles in aqueous solution as a new drug delivery carrier for cancer chemotherapy. The spherical shape of vesicles was confirmed by transmission electron microscopy (TEM) and mean particle sizes were about 33.7 nm, as measured by dynamic light scattering, micro-IR results indicated that the self-assembly vesicles was driven by hydrogen bonding. Hydrophilic doxorubicin (DOX) was successfully loaded into the self-assembly vesicles with drug loading content of 7.85% and loading efficiency of 42%. In addition, an in vitro cytotoxicity study and cellular uptake assays demonstrated that the DOX-loaded Tween 60@2β-CD vesicles markedly enhanced the cellular uptake and cytotoxicity of DOX toward the Hela cells. Furthermore, when used to evaluate the in vivo therapeutic efficacy in mice bearing the breast cell line (4T1), DOX-loaded vesicles exhibited superior inhibition of tumor growth compared with the DOX solutions. Taylor & Francis 2018-02-20 /pmc/articles/PMC7025689/ /pubmed/29463124 http://dx.doi.org/10.1080/10717544.2018.1440448 Text en © 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Yuan, Yue
Zhang, Qin
Yan, Yun
Gong, Miaomiao
Zhao, Qi
Bao, Zhihong
Liu, Kaerdun
Wang, Siling
Designed construction of tween 60@2β-CD self-assembly vesicles as drug delivery carrier for cancer chemotherapy
title Designed construction of tween 60@2β-CD self-assembly vesicles as drug delivery carrier for cancer chemotherapy
title_full Designed construction of tween 60@2β-CD self-assembly vesicles as drug delivery carrier for cancer chemotherapy
title_fullStr Designed construction of tween 60@2β-CD self-assembly vesicles as drug delivery carrier for cancer chemotherapy
title_full_unstemmed Designed construction of tween 60@2β-CD self-assembly vesicles as drug delivery carrier for cancer chemotherapy
title_short Designed construction of tween 60@2β-CD self-assembly vesicles as drug delivery carrier for cancer chemotherapy
title_sort designed construction of tween 60@2β-cd self-assembly vesicles as drug delivery carrier for cancer chemotherapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7025689/
https://www.ncbi.nlm.nih.gov/pubmed/29463124
http://dx.doi.org/10.1080/10717544.2018.1440448
work_keys_str_mv AT yuanyue designedconstructionoftween602bcdselfassemblyvesiclesasdrugdeliverycarrierforcancerchemotherapy
AT zhangqin designedconstructionoftween602bcdselfassemblyvesiclesasdrugdeliverycarrierforcancerchemotherapy
AT yanyun designedconstructionoftween602bcdselfassemblyvesiclesasdrugdeliverycarrierforcancerchemotherapy
AT gongmiaomiao designedconstructionoftween602bcdselfassemblyvesiclesasdrugdeliverycarrierforcancerchemotherapy
AT zhaoqi designedconstructionoftween602bcdselfassemblyvesiclesasdrugdeliverycarrierforcancerchemotherapy
AT baozhihong designedconstructionoftween602bcdselfassemblyvesiclesasdrugdeliverycarrierforcancerchemotherapy
AT liukaerdun designedconstructionoftween602bcdselfassemblyvesiclesasdrugdeliverycarrierforcancerchemotherapy
AT wangsiling designedconstructionoftween602bcdselfassemblyvesiclesasdrugdeliverycarrierforcancerchemotherapy